Trial · Interventional

CompletedPhase 4Results postedRegistry data

Glucagon Use in Colonoscopies

NCTNCT02078726Other id14-13185

Open at ClinicalTrials.govAsk about this trial

Overview

Status: Completed
Phase: Phase 4
Enrollment: 100 participants (actual)
Sponsor: University of California, San Francisco · Other
Design: Randomized · Double masking
Countries: 1 country
United States
Start: Apr 2014
Primary completion: May 2018
Completion: May 2018
First posted: 5 Mar 2014 (estimated)
Last update posted: 3 Jul 2025
Conditions: Colon Cancer

Timeline

1 trial · 1 completed · 1 with posted results

Completed
Ongoing
Not yet recruiting
Stopped
Estimated dates (est.)
Results posted

201420152016201720182019

Ph 4
Glucagon Use in Colonoscopies
NCT02078726
Apr 2014 to May 2018

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

The investigators believe that glucagon therapy will have a positive impact on key parameters of colonoscopy such as cecal intubation time, withdrawal time, total procedure time, adenoma detection rate, endoscopist's assessment of the difficulty of the procedure, patient comfort, and patient's willingness to undergo a repeat colonoscopy.

Interventions

GlucagonDrug

Arms2

Active comparator
Glucagon
1 mg glucagon given during colonoscopy through an IV
Placebo comparator
Placebo
1 mL normal saline given during colonoscopy through an IV

Primary outcomes1

Outcomes the sponsor listed as primary.

Adenoma Detection Rate (ADR) During Colonoscopy Procedure
Time frame · During colonoscopy procedure (an average of 1139 seconds for Glucagon Arm and 1353 seconds for Placebo Arm)
Registry description
ADR was defined as the percentage of participants with at least one traditional adenoma (including tubular or villous adenomas, and adenomas with high grade dysplasia or adenocarcinoma) of any size.

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

Primary outcome results

Primary outcomeNumber· During colonoscopy procedure (an average of 1139 seconds for Glucagon Arm and 1353 seconds for Placebo Arm)

Adenoma Detection Rate (ADR) During Colonoscopy Procedure

Group	Value (percentage of participants)
Glucagon	43.75
Placebo	33.33

Adverse events, as posted

Adverse events as posted: participants affected out of participants at risk, by group
Group	Deaths	Serious events	Other events
Glucagon1 mg glucagon given during colonoscopy Glucagon: glucagon (hormone produced by the body)	0 / 64	0 / 64	0 / 64
Placebo1 mL normal saline Placebo	0 / 36	0 / 36	0 / 36

Each cell reads participants affected / participants at risk, as the registry posted them.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Other registry references

References listed at the registry that are not in PepBank. They link to PubMed.

ResultAnupam Aditi, Trilokesh Dey Kidambi, Angel Espinoza, Nicholas Crowley, Alex Rodas, John Patrick Cello. Glucagon Shortens Cecal Intubation Time and Total Procedure Time During Colonoscopy: A Prospective, Double-Blind Placebo Controlled Randomized Trial. Biomedical Journal of Scientific & Technical Research. 2019; 22(2).

Eligibility

Who could join, as posted.

Sex: All
Age: from 18 Years up to 70 Years
Healthy volunteers: Not accepted

Inclusion and exclusion criteria, as posted

Inclusion Criteria: * Any subject who has already been already cleared for and scheduled to undergo colonoscopy at SFGH endoscopy center. Exclusion Criteria: 1. Refusal to give informed consent. 2. Age \<18 or \>70. 3. Prior intra-abdominal surgery 4. Diabetes 5. Pheochromocytoma 6. Insulinoma 7. Liver disease (Child-Pugh Score \>6) 8. Pregnancy

PepBank is a research reference. Talk to a doctor before you use any peptide.